Loading…
Medicamen Biotech (MEDICAMEQ)₹279.55−0.50%Pharmaceuticals
At the end of the Jun 2026 quarter, Medicamen Biotech's shareholders were: promoters 40.43%, FIIs 0.07%, DIIs 0.40%, government 0.05%, public 59.05%. Promoter holding is unchanged on the quarter. FII holding is up 0.07 percentage points from 0.00% a year earlier. It had 11,051 shareholders.
As of · Company filings (shareholding pattern)
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 43.18% | 43.18% | 43.18% | 42.96% | 42.96% | 42.96% | 43.13% | 40.43% | 40.43% | 40.43% | 40.43% | 40.43% |
| FIIs | 0.22% | 0.22% | 0.12% | 0.06% | 0.06% | 0.06% | 0.12% | 0.00% | 0.05% | 0.02% | 0.10% | 0.07% |
| DIIs | 0.20% | 0.66% | 0.98% | 1.16% | 1.16% | 0.86% | 0.68% | 0.63% | 0.58% | 0.44% | 0.00% | 0.40% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.06% | 0.06% | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% |
| Public | 56.40% | 55.94% | 55.72% | 55.82% | 55.82% | 56.06% | 56.01% | 58.89% | 58.89% | 59.06% | 59.42% | 59.05% |
| Number of shareholders | 9,422 | 10,256 | 10,643 | 10,656 | 10,796 | 10,580 | 10,439 | 10,812 | 11,181 | 10,971 | 10,810 | 11,051 |
| Holder | Category | Jun 2026 | Change (pp) |
|---|---|---|---|
| Shivalik Rasayan Limited | Promoter | 40.43% | 0.00 |
| Pharmadanica A/S | Public | 9.94% | 0.00 |
| Veralogix Holdings(Pty) Ltd | Public | 4.45% | 0.00 |
| Ginnerup Capital Aps | Public | 2.61% | 0.00 |
| Investor Education and Protection Fund (IEPF) | Public | 1.27% | 0.00 |
| Rajesh Madan | Public | 1.15% | 0.00 |
| Ritesh Kantilal Oswal | Public | 1.14% | 0.00 |
| Vijay Amichand Sanghvi | Public | 1.12% | 0.00 |
| Growel Remedies Limited | Promoter | 0.00% | 0.00 |
Promoters held 40.43% of Medicamen Biotech at the end of the Jun 2026 quarter, the same as a year earlier.
In the Jun 2026 quarter, foreign institutional investors (FIIs) held 0.07% (down 0.03 percentage points from 0.10% a quarter earlier) and domestic institutions (DIIs) held 0.40% (up 0.40 percentage points from 0.00% a quarter earlier).
Medicamen Biotech had 11,051 shareholders at the end of the Jun 2026 quarter, against 10,812 a year earlier.
Pharmadanica A/S (Public) held 9.94% at the end of the Jun 2026 quarter, the largest named holding outside the promoter group.